JP2018504450A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504450A5
JP2018504450A5 JP2017546034A JP2017546034A JP2018504450A5 JP 2018504450 A5 JP2018504450 A5 JP 2018504450A5 JP 2017546034 A JP2017546034 A JP 2017546034A JP 2017546034 A JP2017546034 A JP 2017546034A JP 2018504450 A5 JP2018504450 A5 JP 2018504450A5
Authority
JP
Japan
Prior art keywords
nanoparticles
composition according
pharmaceutical composition
pharmaceutical
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504450A (ja
JP6836510B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/077446 external-priority patent/WO2016083343A1/en
Publication of JP2018504450A publication Critical patent/JP2018504450A/ja
Publication of JP2018504450A5 publication Critical patent/JP2018504450A5/ja
Application granted granted Critical
Publication of JP6836510B2 publication Critical patent/JP6836510B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546034A 2014-11-25 2015-11-24 少なくとも2つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 Active JP6836510B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306874 2014-11-25
EP14306874.0 2014-11-25
PCT/EP2015/077446 WO2016083343A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

Publications (3)

Publication Number Publication Date
JP2018504450A JP2018504450A (ja) 2018-02-15
JP2018504450A5 true JP2018504450A5 (enExample) 2019-01-31
JP6836510B2 JP6836510B2 (ja) 2021-03-03

Family

ID=52013981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546034A Active JP6836510B2 (ja) 2014-11-25 2015-11-24 少なくとも2つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用

Country Status (13)

Country Link
US (2) US10391058B2 (enExample)
EP (1) EP3229776B1 (enExample)
JP (1) JP6836510B2 (enExample)
AR (1) AR102781A1 (enExample)
DK (1) DK3229776T3 (enExample)
ES (1) ES2951598T3 (enExample)
FI (1) FI3229776T3 (enExample)
HU (1) HUE062561T2 (enExample)
LT (1) LT3229776T (enExample)
PL (1) PL3229776T3 (enExample)
PT (1) PT3229776T (enExample)
TW (1) TW201628654A (enExample)
WO (1) WO2016083343A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
FI3229776T3 (fi) * 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
DK3236934T3 (da) * 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
US20170258937A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
HK1246160A1 (zh) 2015-05-28 2018-09-07 Nanobiotix 用作治疗性疫苗的纳米粒子
CN115137822B (zh) * 2022-06-13 2023-06-23 武汉大学中南医院 一种光热热电一体化的抗肿瘤植入体的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
AU747051B2 (en) 1997-08-19 2002-05-09 Warner-Lambert Company Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2002002077A2 (en) * 2000-06-30 2002-01-10 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
WO2005063305A1 (en) 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
CA2555343A1 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
WO2009026427A2 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
JP5649137B2 (ja) 2010-02-17 2015-01-07 国立大学法人神戸大学 放射線治療剤
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
CA2816155C (en) 2010-12-17 2020-10-27 Arrowhead Research Corporation Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
PL2670394T3 (pl) * 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
UA116380C2 (uk) * 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
US20170258937A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
WO2016083336A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
DK3236934T3 (da) 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
FI3229776T3 (fi) * 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt

Similar Documents

Publication Publication Date Title
JP2018504450A5 (enExample)
JP2016522833A5 (enExample)
JP2016513657A5 (enExample)
JP2017514800A5 (enExample)
JP2013503174A5 (enExample)
EP4282430A3 (en) Garp-tgf-beta antibodies
WO2009053644A3 (fr) Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants
HK1212616A1 (zh) 多孔载体颗粒和微粒化药物的可吸入团聚物
JP2016512513A5 (enExample)
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
WO2015017821A3 (en) Therapeutically active compounds and their methods of use
JP2004534850A5 (enExample)
JP2010523696A5 (enExample)
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
JP2018538273A5 (enExample)
JP2018527287A5 (enExample)
RU2018119680A (ru) Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина
AR102781A1 (es) Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
JP2012529293A5 (enExample)
JP2016526021A5 (enExample)
Vanea et al. XPS and Raman study of zinc containing silica microparticles loaded with insulin
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
JP2015512420A5 (enExample)